Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2022-03-30 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于续聘2022年度会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (auditor) for the fiscal year 2022. It details the auditor's background, independence, audit fees, and the approval process by the audit committee, independent directors, and the board of directors. There is no actual audit report or financial statements included, only information about the auditor appointment and related procedures. The document length is 2744 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of Audit Report / Information (AR), as it relates to audit firm appointment and audit-related disclosures but is not a full annual report or audit report itself. The document is not a report publication announcement or regulatory filing since it contains substantive information about the auditor and audit process, not just a notice of report availability. FY 2022
2022-03-30 Chinese
天士力2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 Annual Report Summary" of TianShiLi Pharmaceutical Group Co., Ltd. It contains detailed sections on company overview, business analysis, research and development progress, marketing, manufacturing, strategic planning, and industry position. It includes comprehensive financial and operational data for the fiscal year 2021, with specific profit distribution plans and audited financial figures. The document is lengthy (15,000 characters) and contains substantive financial and business information, not merely an announcement or a brief summary. It is clearly a full annual report or a detailed summary derived from the full annual report, covering the company's yearly performance and outlook. Therefore, the appropriate classification is Annual Report (10-K). FY 2021
2022-03-30 Chinese
天士力关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by the company TianShiLi Pharmaceutical Group Co., Ltd. It details the reasons for the change, the impact on financial statement line items, and includes opinions from independent directors and the supervisory board. The document does not contain full financial statements or comprehensive financial performance data, but rather explains a specific accounting policy change and its effects. It is not a full Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is also not a brief announcement of a report publication. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about accounting policy changes required by the Ministry of Finance and related regulatory bodies, without being a full financial report itself.
2022-03-30 Chinese
天士力独立董事关于公司第八届董事会第11次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the company's 8th board of directors 11th meeting. It includes opinions on the 2021 profit distribution plan, internal control evaluation report, related party transactions, guarantees for subsidiaries, reappointment of the accounting firm for 2022, and accounting policy changes. The document references regulatory guidelines and legal compliance but does not contain actual financial statements or detailed financial data. It is a formal opinion letter related to board meeting matters rather than a full financial report or audit report. Given the nature of the document as an independent director's opinion on board meeting items, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification letter, so it is not RPA or RNS.
2022-03-30 Chinese
天士力第八届董事会第11次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 8th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals such as the 2021 annual general manager work report, board work report, audit committee report, accounting policy changes, financial statements, profit distribution plan, social responsibility report, internal control reports, related party transactions, guarantees, credit line applications, and appointment of accounting firms. It also references the upcoming 2021 Annual General Meeting (AGM) and related documents published on the Shanghai Stock Exchange website. The document is not the reports themselves but an official announcement of the board meeting resolutions and voting outcomes. The length is under 5,000 characters and it repeatedly states that full reports are available on the exchange website, indicating this is an announcement rather than the reports themselves. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-03-30 Chinese
天士力2021年度审计委员会述职报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度审计委员会述职报告' which translates to '2021 Annual Audit Committee Work Report'. It details the audit committee's activities, including supervision of external and internal audits, evaluation of internal controls, and review of financial reports for the year 2021. It is a report from the audit committee to the board summarizing audit-related work and findings for the year. The document is relatively short (1402 characters) and does not contain full financial statements or detailed financial data, but rather a summary and evaluation of audit activities and internal controls. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal audits. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements. It is not a Regulatory Filing (RNS) because it is a substantive report, not a certification or brief announcement. Therefore, the best classification is AR with high confidence. FY 2021
2022-03-30 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.